19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pfs230 is a leading malaria transmission blocking vaccine (TBV) candidate. Comprising 3135 amino acids (aa), the large size of Pfs230 necessitates the use of sub-fragments as vaccine immunogens. Therefore, determination of which regions induce functional antibody responses is essential. We previously reported that of 27 sub-fragments spanning the entire molecule, only five induced functional antibodies. A “functional” antibody is defined herein as one that inhibits Plasmodium falciparum parasite development in mosquitoes in a standard membrane-feeding assay (SMFA). These five sub-fragments were found within the aa 443–1274 range, and all contained aa 543–730. Here, we further pinpoint the location of epitopes within Pfs230 that are recognized by functional antibodies using antibody depletion and enrichment techniques. Functional epitopes were not found within the aa 918–1274 region. Within aa 443–917, further analysis showed the existence of functional epitopes not only within the aa 543–730 region but also outside of it. Affinity-purified antibodies using a synthetic peptide matching aa 543–588 showed activity in the SMFA. Immunization with a synthetic peptide comprising this segment, formulated either as a carrier-protein conjugate vaccine or with a liposomal vaccine adjuvant system, induced antibodies in mice that were functional in the SMFA. These findings provide key insights for Pfs230-based vaccine design and establish the feasibility for the use of synthetic peptide antigens for a malaria TBV.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.

          Enzyme linked immunosorbent assay (ELISA) has been widely used to measure antibody titers for evaluating the immunogenicity of a vaccine. However, there is as yet no generally accepted way of expressing the ELISA results in the case of experimental vaccines, since there is usually no uniform standard. Both end point and single dilution methods have significant disadvantages. In this paper, we obtained reproducible data with fewer dilutions of samples by addition of serially diluted standard serum to each ELISA plate. Since this ELISA method gives reliable antibody titer with less labor than other methods, it can strongly support vaccine development.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays

            Vaccines that interrupt malaria transmission are of increasing interest and a robust functional assay to measure this activity would promote their development by providing a biologically relevant means of evaluating potential vaccine candidates. Therefore, we aimed to qualify the standard membrane-feeding assay (SMFA). The assay measures the transmission-blocking activity of antibodies by feeding cultured P. falciparum gametocytes to Anopheles mosquitoes in the presence of the test antibodies and measuring subsequent mosquito infection. The International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline Q2(R1) details characteristics considered in assay validation. Of these characteristics, we decided to qualify the SMFA for Precision, Linearity, Range and Specificity. The transmission-blocking 4B7 monoclonal antibody was tested over 6 feeding experiments at several concentrations to determine four suitable concentrations that were tested in triplicate in the qualification experiments (3 additional feeds) to evaluate Precision, Linearity and Range. For Specificity, 4B7 was tested in the presence of normal mouse IgG. We determined intra- and inter-assay variability of % inhibition of mean oocyst intensity at each concentration of 4B7 (lower concentrations showed higher variability). We also showed that % inhibition was dependent on 4B7 concentration and the activity is specific to 4B7. Since obtaining empirical data is time-consuming, we generated a model using data from all 9 feeds and simulated the effects of different parameters on final readouts to improve the assay procedure and analytical methods for future studies. For example, we estimated the effect of number of mosquitoes dissected on variability of % inhibition, and simulated the relationship between % inhibition in oocyst intensity and % inhibition of prevalence of infected mosquitos at different mean oocysts in the control. SMFA is one of the few biological assays used in preclinical and early clinical development of transmission-blocking vaccines, and this study strongly supports its further development and application.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum

              Malaria transmission-blocking vaccines (TBVs) target the development of Plasmodium parasites within the mosquito, with the aim of preventing malaria transmission from one infected individual to another. Different vaccine platforms, mainly protein-in-adjuvant formulations delivering the leading candidate antigens, have been developed independently and have reported varied transmission-blocking activities (TBA). Here, recombinant chimpanzee adenovirus 63, ChAd63, and modified vaccinia virus Ankara, MVA, expressing AgAPN1, Pfs230-C, Pfs25, and Pfs48/45 were generated. Antibody responses primed individually against all antigens by ChAd63 immunization in BALB/c mice were boosted by the administration of MVA expressing the same antigen. These antibodies exhibited a hierarchy of inhibitory activity against the NF54 laboratory strain of P. falciparum in Anopheles stephensi mosquitoes using the standard membrane feeding assay (SMFA), with anti-Pfs230-C and anti-Pfs25 antibodies giving complete blockade. The observed rank order of inhibition was replicated against P. falciparum African field isolates in A. gambiae in direct membrane feeding assays (DMFA). TBA achieved was IgG concentration dependent. This study provides the first head-to-head comparative analysis of leading antigens using two different parasite sources in two different vector species, and can be used to guide selection of TBVs for future clinical development using the viral-vectored delivery platform.
                Bookmark

                Author and article information

                Contributors
                tsuboi.takafumi.mb@ehime-u.ac.jp
                Journal
                NPJ Vaccines
                NPJ Vaccines
                NPJ Vaccines
                Nature Publishing Group UK (London )
                2059-0105
                13 January 2022
                13 January 2022
                2022
                : 7
                : 4
                Affiliations
                [1 ]GRID grid.94365.3d, ISNI 0000 0001 2297 5165, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, , National Institutes of Health, ; 12735 Twinbrook Parkway, Rockville, MD 20852 USA
                [2 ]GRID grid.255464.4, ISNI 0000 0001 1011 3808, Division of Malaria Research, Proteo-Science Center, , Ehime University, ; Matsuyama, Ehime 790-8577 Japan
                [3 ]GRID grid.273335.3, ISNI 0000 0004 1936 9887, Department of Biomedical Engineering, , University at Buffalo, State University of New York, ; Buffalo, NY 14260 USA
                [4 ]GRID grid.255464.4, ISNI 0000 0001 1011 3808, Division of Molecular Parasitology, Proteo-Science Center, , Ehime University, ; Toon, Ehime 791-0295 Japan
                [5 ]GRID grid.415269.d, ISNI 0000 0000 8940 7771, PATH’s Malaria Vaccine Initiative (MVI), ; Washington, DC 20001 USA
                [6 ]GRID grid.265073.5, ISNI 0000 0001 1014 9130, Present Address: Department of Environmental Parasitology, Graduate School of Medical and Dental Sciences, , Tokyo Medical and Dental University, ; Tokyo, Japan
                Author information
                http://orcid.org/0000-0003-4455-2432
                http://orcid.org/0000-0001-9070-8499
                http://orcid.org/0000-0002-9052-884X
                http://orcid.org/0000-0002-7415-1325
                Article
                423
                10.1038/s41541-021-00423-3
                8758780
                35027567
                fc1b1cc3-f166-4054-9385-454edc37ff9c
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 30 June 2021
                : 30 November 2021
                Funding
                Funded by: FundRef https://doi.org/10.13039/100006492, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID);
                Funded by: FundRef https://doi.org/10.13039/100005624, PATH (Program for Appropriate Technology in Health);
                Funded by: FundRef https://doi.org/10.13039/501100001691, MEXT | Japan Society for the Promotion of Science (JSPS);
                Award ID: JP20H03481
                Award ID: JP21H02724
                Award ID: JP20H03480
                Award ID: JP20H03480
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100000060, U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID);
                Award ID: R01AI148557
                Award ID: R01AI148557
                Award ID: R01AI148557
                Award Recipient :
                Funded by: Global Health Innovative Technology (GHIT) Fund
                Funded by: PATH’s Malaria Vaccine Initiative
                Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
                Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                peptide vaccines,parasitic infection
                peptide vaccines, parasitic infection

                Comments

                Comment on this article